Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey PC149 (#8)
Pablo García‐Pavía(Universidad Francisco de Vitoria), Mat Maurer, Brian Drachman(Penn Presbyterian Medical Center), Martin Carlsson(Pfizer (United States)), Leslie Amass(Pfizer (United States)), V. Arnt, Franca S. Angeli(Pfizer (United States))
Cited by 1
Related Papers
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction
|European Heart Journal|2015|1.1k